– USA, NC – Oerth Bio, an agricultural biotech company pioneering targeted protein modulation for plant health applications, today announced the appointment of Thong Le to its Board as an independent director.
“We are pleased to welcome Thong to the board of Oerth Bio. He brings with him a wealth of knowledge and experience in building and managing successful biotech companies at a time when Oerth Bio is significantly progressing its platform technologies, pipeline of unique products, and important strategic partnerships. He will prove invaluable to Oerth Bio in supporting many of our decisions as the company further matures,” said CEO, John Dombrosky.
About Thong Q. Le
Mr. Le brings considerable experience to the board of Oerth Bio. He currently serves as Senior Managing Director and Chief Executive Officer of Accelerator Life Science Partners and has more than 20 years of experience in identifying, investing in, managing, and successfully exiting numerous seed and early-stage investments in the biotechnology sector. He has served as the founding CEO and director of numerous Accelerator Life Science Partners portfolio companies, including Petra Pharma (substantial acquisition by a global pharmaceutical company in May 2020), Rodeo Therapeutics (acquired by Amgen Inc. for up to $721 million in March 2021), and Lodo Therapeutics (acquired by Zymergen in May 2021). He currently oversees the firm’s investments in ALSP ORCHID Acquisition Corporation I (NASDAQ: ALORU | ALOR), Lydian Neurosciences, Magnolia Neurosciences, and Proniras Corporation, where he also serves as Chief Executive Officer and Director of each company.
Before joining Accelerator Life Science Partners, Mr. Le served as a Managing Director at WRF Capital, the venture capital investment arm of Washington Research Foundation where he played a significant role in the early sourcing, financing, and development of numerous life science companies, including Alder Biopharmaceuticals (acquired by H. Lundbeck A/S), Corus Pharma (acquired by Gilead Sciences), Halosource (LON: HALO), Hyperion Therapeutics (acquired by Horizon Pharma plc), Lumera, Pathway Medical Technologies (acquired by MEDRAD), and VLST (asset acquisition by a global pharmaceutical company). Before joining WRF Capital, Mr. Le held various roles at MiniMeals and Capital Management Consulting. Mr. Le completed post-graduate studies at the Templeton College of Oxford University and received his A.B. cum laude in Government from Harvard University.
Mr. Le’s addition to the board comes at a critical time, as Oerth Bio accelerates its proprietary Attune platform to produce PROTAC molecules that protect, fine-tune, and biostimulate crops facing significant threats. The company’s ambition is to reduce the environmental impact of agriculture and nourish a growing population, without compromising on-farm demands. By harnessing the plant’s natural protein harmonization bio machinery, Oerth Bio is first-in-the-world to overcome legacy small molecule limitations while retaining their key advantages.
“I am delighted to join Oerth Bio, an innovative agricultural biotechnology company that has pioneered a unique and disruptive platform technology,” said Thong Q. Le. “Oerth Bio’s Attune platform is capable of developing unique molecules that address unmet industry needs in crop protection and plant health, and the stage is set to build upon the many successes that have already been achieved by the talented Oerth Bio team. I look forward to supporting Oerth Bio and contributing to the company’s continued success.”
About Oerth Bio
Oerth Bio is an agricultural biotech company working to reduce the environmental impact of agrochemical solutions and nourish a growing population with the eco-friendly, healthy foods it demands. The company develops sustainable, environmentally-designed crop and farm solutions with unprecedented ability to fine-tune crops—protecting them from pests, enhancing resilience to changing environmental stressors, increasing nutritional value, and strengthening post-harvest durability.
Oerth Bio was formed as a joint venture between Arvinas and Bayer, supported by $56 million in committed funding and operational support from Bayer, and technology and intellectual property from Arvinas. Oerth Bio is located in Durham, North Carolina.
For more information: https://www.oerthbio.com/
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.